Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
Conditions:   Advanced Colorectal Carcinoma;   Advanced Digestive System Carcinoma;   Advanced Gastric Carcinoma;   Advanced Gastroesophageal Junction Adenocarcinoma;   Clinical Stage III Gastric Cancer AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Metastatic Colorectal Carcinoma;   Metastatic Digestive System Carcinoma;   Metastatic Gastric Carcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage III Gastric Cancer AJCC v8;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastric Cancer AJCC v8;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Gastric Cancer AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIC Gastric Cancer AJCC v8;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Stage III Colorectal Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8
Interventions:   Drug: Elimusertib;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Drug: Leucovorin Calcium
Sponsor:   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 22, 2021 / by / in
Comments